Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bissan Al-Lazikani

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Future Medicinal Chemistry|September 2, 2016
Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactomeBissan Al-Lazikani, Paul Workman
Nature Reviews. Drug Discovery|November 30, 2013
Drugging cancer genomesPaul Workman, Bissan Al-Lazikani
Cancer Discovery|January 16, 2013
Unpicking the combination lock for mutant BRAF and RAS melanomasBissan Al-Lazikani, Paul Workman
Nature Biotechnology|July 12, 2012
Combinatorial drug therapy for cancer in the post-genomic eraBissan Al-Lazikani, Udai Banerji, Paul Workman
Cancer Cell|April 21, 2012
Personalized medicine: patient-predictive panel powerPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Journal of Molecular Biology|November 26, 2003
Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domainsFelix B Sheinerman, Bissan Al-Lazikani, Barry Honig
Current Opinion in Pharmacology|July 2, 2013
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncologyPaul Workman, Bissan Al-Lazikani, Paul A Clarke
Methods in Molecular Biology (Clifton, N.J.)|August 21, 2008
Protein structure predictionBissan Al-Lazikani, Emma E Hill, Veronica Morea
Oncotarget|January 29, 2016
Blocking the survival of the nastiest by HSP90 inhibitionPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Future Medicinal Chemistry|September 2, 2016
Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactomeBissan Al-Lazikani, Paul Workman
Nature Reviews. Drug Discovery|November 30, 2013
Drugging cancer genomesPaul Workman, Bissan Al-Lazikani
Cancer Discovery|January 16, 2013
Unpicking the combination lock for mutant BRAF and RAS melanomasBissan Al-Lazikani, Paul Workman
Nature Biotechnology|July 12, 2012
Combinatorial drug therapy for cancer in the post-genomic eraBissan Al-Lazikani, Udai Banerji, Paul Workman
Cancer Cell|April 21, 2012
Personalized medicine: patient-predictive panel powerPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Journal of Molecular Biology|November 26, 2003
Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domainsFelix B Sheinerman, Bissan Al-Lazikani, Barry Honig
Current Opinion in Pharmacology|July 2, 2013
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncologyPaul Workman, Bissan Al-Lazikani, Paul A Clarke
Methods in Molecular Biology (Clifton, N.J.)|August 21, 2008
Protein structure predictionBissan Al-Lazikani, Emma E Hill, Veronica Morea
Oncotarget|January 29, 2016
Blocking the survival of the nastiest by HSP90 inhibitionPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Pageof 7